Patient-centric trials for therapeutic development in precision oncology

Andrew V. Biankin, Steven Piantadosi, Simon J. Hollingsworth

    Research output: Contribution to journalReview article

    Abstract

    An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours. Considerable associated challenges include how to advance and implement targeted drug-development strategies. Precision medicine centres on delivering the most appropriate therapy to a patient on the basis of clinical and molecular features of their disease. The development of therapeutic agents that target molecular mechanisms is driving innovation in clinical-trial strategies. Although progress has been made, modifications to existing core paradigms in oncology drug development will be required to realize fully the promise of precision medicine.

    Original languageEnglish (US)
    Pages (from-to)361-370
    Number of pages10
    JournalNature
    Volume526
    Issue number7573
    DOIs
    StatePublished - Oct 14 2015

      Fingerprint

    ASJC Scopus subject areas

    • General

    Cite this

    Biankin, A. V., Piantadosi, S., & Hollingsworth, S. J. (2015). Patient-centric trials for therapeutic development in precision oncology. Nature, 526(7573), 361-370. https://doi.org/10.1038/nature15819